Review Article

American Journal of Clinical Dermatology

, Volume 14, Issue 4, pp 261-272

First online:

Immunotherapy for the Management of Advanced Melanoma: The Next Steps

  • Dragoslav ZikichAffiliated withElla Institute for Melanoma, Sheba Medical Center
  • , Jacob SchachterAffiliated withElla Institute for Melanoma, Sheba Medical Center
  • , Michal J. BesserAffiliated withElla Institute for Melanoma, Sheba Medical CenterDepartment of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.